Acurx Pharmaceuticals (ACXP) Competitors $1.86 -0.02 (-1.06%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACXP vs. GLMD, INDP, AYTU, AGRX, ME, IPSC, OPTN, ANRO, DERM, and ACRSShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Galmed Pharmaceuticals (GLMD), Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), Agile Therapeutics (AGRX), 23andMe (ME), Century Therapeutics (IPSC), OptiNose (OPTN), Alto Neuroscience (ANRO), Journey Medical (DERM), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Galmed Pharmaceuticals Indaptus Therapeutics Aytu BioPharma Agile Therapeutics 23andMe Century Therapeutics OptiNose Alto Neuroscience Journey Medical Aclaris Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Do analysts rate GLMD or ACXP? Acurx Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 545.16%. Given Acurx Pharmaceuticals' higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAcurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GLMD or ACXP more profitable? Galmed Pharmaceuticals' return on equity of -27.06% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -27.06% -23.47% Acurx Pharmaceuticals N/A -371.20%-219.01% Does the MarketBeat Community believe in GLMD or ACXP? Galmed Pharmaceuticals received 430 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 92.31% of users gave Acurx Pharmaceuticals an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGalmed PharmaceuticalsOutperform Votes44263.69% Underperform Votes25236.31% Acurx PharmaceuticalsOutperform Votes1292.31% Underperform Votes17.69% Do institutionals and insiders believe in GLMD or ACXP? 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, GLMD or ACXP? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$6.91M-$17.23-0.19Acurx PharmaceuticalsN/AN/A-$14.58M-$1.16-1.60 Does the media prefer GLMD or ACXP? In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Acurx Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.49 beat Acurx Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Galmed Pharmaceuticals Neutral Acurx Pharmaceuticals Neutral Which has more risk & volatility, GLMD or ACXP? Galmed Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500. SummaryGalmed Pharmaceuticals beats Acurx Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.23M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.609.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book5.475.324.665.02Net Income-$14.58M$153.56M$119.06M$225.46M7 Day Performance1.09%0.11%0.80%0.37%1 Month Performance-13.49%15.22%5.65%3.57%1 Year Performance-51.05%41.14%36.76%29.44% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals1.2202 of 5 stars$1.86-1.1%$12.00+545.2%-63.3%$30.23MN/A-1.603Positive NewsGLMDGalmed Pharmaceuticals2.0735 of 5 stars$3.90-0.8%N/A-32.5%$19.68MN/A-0.2320INDPIndaptus Therapeutics3.9584 of 5 stars$1.54+14.1%$12.00+679.2%-49.8%$13.15MN/A-0.836Upcoming EarningsShort Interest ↓AYTUAytu BioPharma1.0503 of 5 stars$2.08-3.7%N/A-28.2%$12.44M$81.00M-0.73160Short Interest ↓Positive NewsGap UpAGRXAgile Therapeutics0.1571 of 5 stars$1.51flatN/A-17.5%$10.35M$19.98M-0.4130Analyst ForecastME23andMe1.9247 of 5 stars$4.85+3.9%$9.40+93.8%-71.6%$118.87M$219.64M-0.19770Gap DownIPSCCentury Therapeutics1.768 of 5 stars$1.40+0.7%$12.75+810.7%-15.4%$118.30M$2.04M-0.69170Positive NewsOPTNOptiNose3.411 of 5 stars$0.78+1.3%$4.00+410.5%-45.7%$118.14M$70.99M-2.18190Gap DownANROAlto Neuroscience2.3264 of 5 stars$4.22-3.4%$24.40+478.2%N/A$117.48M$210,000.000.00N/ADERMJourney Medical3.4208 of 5 stars$6.00+4.2%$9.38+56.3%N/A$115.28M$77.68M-300.0090Upcoming EarningsShort Interest ↓ACRSAclaris Therapeutics3.3062 of 5 stars$1.61-4.7%$9.00+459.0%-58.9%$114.74M$32.02M-1.9686Upcoming EarningsPositive News Related Companies and Tools Related Companies Galmed Pharmaceuticals Alternatives Indaptus Therapeutics Alternatives Aytu BioPharma Alternatives Agile Therapeutics Alternatives 23andMe Alternatives Century Therapeutics Alternatives OptiNose Alternatives Alto Neuroscience Alternatives Journey Medical Alternatives Aclaris Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACXP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
